Adaptive Biotechnologies Corp
ADPTQ2 2025(ADPT Q1 FY2025)Derived8% AI
AI Revenue %
8%
AI Fair Value
$137.4M
AI Revenue (Q)
$3.3M
Total Revenue (Q)
$41.9M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Total revenue $52.4M. MRD: $43.7M. Immune Medicine: $8.7M. MRD growing strongly (34% YoY) from clonoSEQ Medicare pricing increase (17% increase to $8,029 per episode) and MCL coverage expansion. IM at $8.7M is steady-state (no milestone). Applying 50% AI attribution to IM: $8.7M * 50% = $4.4M. AI Revenue % = $4.4M / $52.4M = 8.4%, rounded to 8%.
Analyzed by claude-opus-4-6
Quoted Figures
MRD Revenue $43,721K, Immune Medicine Revenue $8,722K, Total $52,443K for Q1 2025
10-Q filed 2025-05-07, Segment Information note
We also obtained a new Medicare Clinical Laboratory Fee Schedule rate of $2,007 per test for clonoSEQ and MolDX updated the clonoSEQ episode pricing to $8,029 for all covered indications
10-Q filed 2025-05-07, MD&A Overview
AI Products Identified (Ring 1)
TCR-Antigen Map (AI/ML-driven immune receptor-disease mapping)Adaptive Immunosequencing (AI/ML analysis)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
clonoSEQ diagnostic test ($43.7M MRD segment, NGS-based)MRD Pharma testing services
Confidence Tier
DerivedCalculated from reported segments primarily serving AI